10th Jul 2015 13:37
10 July 2015
Motif Bio Plc
(the "Company")
Result of General Meeting
Motif Bio plc, the clinical stage biopharmaceutical company specialising in developing novel antibiotics, is pleased to announce that at the General Meeting held earlier today all resolutions as set out in the Notice of General Meeting annexed to the circular to shareholders dated 23 June 2015 were duly passed. The passing of the resolutions represents the satisfaction of the first of the two conditions to completion of the conditional placing of 44,000,000 ordinary shares announced by the Company on 23 June 2015.
The second condition, being the successful grant of the QIDP designation for iclaprim in the US (such grant not to be later than 24 July 2015), remains to be satisfied.
Enquiries:
Motif Bio plc Graham Lumsden (Chief Executive Officer) Robert Bertoldi (Chief Financial Officer) www.motifbio.com
| |
Zeus Capital Limited (NOMINATED ADVISER & JOINT BROKER) Phil Walker/John Treacy/Dominic Wilson
| +44 (0) 207 183 5860 |
Northland Capital Partners Limited (JOINT BROKER) Gerry Beaney/David Hignell John Howes/Mark Treharne (Broking)
| +44 (0) 20 7382 1100 |
Plumtree Capital Limited (FINANCIAL ADVISER) | +44 (0) 207 183 2493 |
Stephen Austin
| |
Yellow Jersey PR Limited (FINANCIAL PR) Dominic Barretto/Philip Ranger/Fiona Walker
MC Services (TRADE PR) Raimund Gabriel Shaun Brown | +44 (0) 7768 537 739
+49 (0) 89 210 2280 +44 (0) 207 148 5998 |
Notes to Editors:
Motif is a clinical stage biopharmaceutical company, which specialises in developing novel antibiotics designed to be effective against serious and life-threatening infections caused by multi-drug resistant bacteria. The Company has a lead antibiotic candidate, iclaprim, in clinical development and MTF-001, a preclinical stage programme to design a best-in-class dihydrofolate reductase inhibitor (DHFRi).
Iclaprim is being developed for the treatment of the most common and serious bacterial infections such as acute bacterial skin and skin structure infections (ABSSSI) and hospital acquired bacterial pneumonia (HABP), including those caused by resistant strains such as MRSA (methicillin-resistant Staphylococcus aureus) and MDRSP (multi-drug resistant Streptococcus pneumoniae) that have become prevalent in patients in both the community and hospital settings.
Related Shares:
MTFB.L